NCT00993460

Brief Summary

Research has shown that fat stored within muscles affects the muscle's sensitivity to insulin and ability to handle blood glucose. The purpose of this study is to examine the effects of weight loss surgery-induced caloric restriction on the accumulation and types of fats within skeletal muscle, as well as the effects of such caloric restriction on insulin sensitivity and inflammatory responses in skeletal muscle. The investigator proposes that caloric restriction will result in decreases in diacylglycerols enriched with saturated fat and increases in diacylglycerols enriched with monounsaturated fats.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for all trials

Timeline
6mo left

Started Mar 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress97%
Mar 2011Nov 2026

First Submitted

Initial submission to the registry

October 7, 2009

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 12, 2009

Completed
1.4 years until next milestone

Study Start

First participant enrolled

March 1, 2011

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
13 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Expected
Last Updated

July 8, 2025

Status Verified

July 1, 2025

Enrollment Period

2.7 years

First QC Date

October 7, 2009

Last Update Submit

July 2, 2025

Conditions

Keywords

ObesityInsulin sensitivityInflammation

Outcome Measures

Primary Outcomes (1)

  • UPLC-ESI MS/MS profiling of lipd extracts from muscle biopsies to evaluate effects of gastric bypass induced-caloric restriction on diacylglycerol molecular species accumulation.

    1 year

Secondary Outcomes (2)

  • To evaluate the effects of gastric bypass induced-caloric restriction on skeletal muscle insulin action via a hyperinsulinemic-euglycemic clamp and profiling markers of insulin signaling.

    1 year

  • To evaluate the effects of gastric bypass induced-caloric restriction on lipid-mediated inflammatory responses by profiling cytokines and free fatty acids in blood and inflammation markers in skeletal muscle biopsies.

    1 year

Study Arms (2)

Normal body weight

Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.

Roux-en-Y gastric bypass

Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.

Eligibility Criteria

Age21 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Female subjects approved for Roux-en-Y gastric bypass surgery at Vanderbilt University Medical Center.

You may qualify if:

  • For Normal Weight Subjects:
  • Age 21-65 years
  • BMI of 21 to 27 kg/m2
  • Normal glucose tolerance as determined by OGTT on day of screening
  • No family history of diabetes
  • For Morbidly Obese Subjects:
  • Age 21-65 years
  • BMI of 30 to 65 kg/m2
  • Scheduled for Roux-en-Y gastric bypass at Vanderbilt Medical Center
  • Insulin resistant as determined by OGTT on day of screening

You may not qualify if:

  • Clinically significant heart disease
  • Clinically significant hepatic or renal disease
  • Pregnancy
  • Breastfeeding
  • Any abnormality that would preclude safe completion of study
  • Use of statins
  • Use of thiazide or furosemide diuretics, beta blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless subject has been on stable dose of such medications for the past 3 months before entering the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood, plasma, muscle tissue

MeSH Terms

Conditions

ObesityInsulin ResistanceInflammation

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesPathologic Processes

Study Officials

  • Charles R Flynn, PhD

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR
  • Naji Abumrad, MD

    Vanderbilt University Medical Center

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

October 7, 2009

First Posted

October 12, 2009

Study Start

March 1, 2011

Primary Completion

November 1, 2013

Study Completion (Estimated)

November 1, 2026

Last Updated

July 8, 2025

Record last verified: 2025-07

Locations